<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571412</url>
  </required_header>
  <id_info>
    <org_study_id>01-05/05/2016</org_study_id>
    <nct_id>NCT03571412</nct_id>
  </id_info>
  <brief_title>Antidepressive Effect on 5 Herz (Hz) rTMS Over Dorsomedial Prefrontal Cortex and Left Dorsolateral Prefrontal Cortex</brief_title>
  <official_title>Comparative of Antidepressive Effect on 5Hz rTMS on Dorsomedial Prefrontal Cortex and Left Dorsolateral Prefrontal Cortex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de Queretaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de Queretaro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of 5Hz repetitive Transcranial Magnetic Stimulation (rTMS)
      over Left Dorsolateral Prefrontal Cortex and Dorsomedial Prefrontal Cortex on Major
      Depressive Disorder (MDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major Depressive Disorder (MDD) affects a significant percentage of the national population
      (17-20%) in 2:1 ratio in women compared to men. Repetitive Transcranial Magnetic Stimulation
      (rTMS) is an effective neuromodulation technique for the treatment of Major Depressive
      Disorder and it has demonstrated favorable clinical effects when applied over the Left
      Dorsolateral Prefrontal Cortex (LDLPFC); however there is evidence that other areas of the
      prefrontal cortex such as the Dorsomedial Prefrontal Cortex (DMPFC) could be ideal for rTMS
      treatment targets during the presence of MDD, given its association with deficient cognitive
      processes during the course of the illness. There is also evidence of the use of 5Hz
      frequency with the same clinical effectiveness from other frequencies such as 10 Hz and 20 Hz
      when applied to the LDLPFC. However, there are no current research that have addressed the
      use of this frequency on DMPFC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2016</start_date>
  <completion_date type="Actual">September 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The purpose to this study is to valuate the clinical effects of 5Hz rTMS over Left Dorsolateral Prefrontal Cortex and Dorsomedial Prefrontal Cortex</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in depressive symptoms evaluated by Hamilton Depressive Rating Scale (HADRS)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Hamilton Depressive Rating Scale (HADRS) is a 21 item clinimetric scale to evaluate severity of depressive symptoms in patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in depressive symptoms evaluated by Montgomery-Asberg Depressive Rating Scale (MADRS)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Montgomery- Asberg Depressive Rating Scale (MADRS) is a 10 item clinimetric scale that evaluates the presence and severity of depressive symptoms in subjects with the disorder mentioned before.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>5Hz Left Dorsolateral Prefrontal Cortex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive 5Hz Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation. Once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5Hz Dorsomedial Prefrontal Cortex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS</description>
    <arm_group_label>5Hz Dorsomedial Prefrontal Cortex</arm_group_label>
    <arm_group_label>5Hz Left Dorsolateral Prefrontal Cortex</arm_group_label>
    <other_name>Transcranial Magnetic Stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-45 years old.

          -  Meet DSM 5 (Diagnostic and Statistical Manual, 5 edition) diagnostic criteria for
             Major Depressive Disorder.

          -  Score &gt;17 in Hamilton Depression Rating Scale.

        Exclusion Criteria:

          -  Subjects with diagnose of Psychotic Depression, Schizophrenia, Bipolar Disorder, Post
             Traumatic Stress Disorder.

          -  Subjects with epilepsy or presence of paroxysms during the EEG.

          -  Subjects with previous history of traumatic brain injury, metal plates in the skull,
             cochlear devices, infusion devices such as insulin pumps.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Reyes, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad Autónoma de Querétaro</affiliation>
  </overall_official>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de Queretaro</investigator_affiliation>
    <investigator_full_name>Dr. Julian Reyes López</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

